

DOI: 10.13241/j.cnki.pmb.2014.05.047

· 专论与综述 ·

巨噬细胞凋亡对结核分枝杆菌感染的机制研究进展*

于翔¹ 陆佳嘉² 王秦² 于晓姝³ 杨永青^{1△}

(1 中国农业大学生物学院生化系 北京 100094; 2 第二军医大学学员旅 9 队 上海 200433;

3 军事医学科学院基础所 北京 100850)

摘要: 结核病是一种严重危害人类健康的慢性传染性疾病, 主要由结核分枝杆菌感染导致, 结核分枝杆菌进入人体后, 与免疫防御的第一道屏障—巨噬细胞发生反应, 部分菌株在细胞内长期生存、繁殖, 是导致结核病转归的决定性因素。感染早期, 结核分枝杆菌的繁殖受到巨噬细胞凋亡的抑制, 随着高效价、高毒力菌株繁殖速度的增加, 抗巨噬细胞凋亡作用不断增强, 使自身繁殖得到有效保护, 为菌株的生长提供了充足、适宜的胞内环境。因此, 调控结核分枝杆菌对巨噬细胞凋亡进程的抑制作用, 是预防和治疗结核病的关键。

关键词: 巨噬细胞; 凋亡; 结核分枝杆菌; 感染; 机制; 进展

中图分类号: R378.911, R52 **文献标识码:** A **文章编号:** 1673-6273(2014)05-972-03

Progress of Research on the Mechanism of Apoptosis of Macrophages Infected with Mycobacterium Tuberculosis*

YU Xiang¹, LU Jia-jia², WANG Qin², YU Xiao-shen³, YANG Yong-qing^{1△}

(1 college of biological science, China Agricultural University, Beijing, 100094, China;

2 students ride 9 team of the second military medical university, Shanghai, 200433, China;

3 Institute of Basic Medical Sciences, academy of military medical sciences, Beijing, 100850, China)

ABSTRACT: Tuberculosis is a chronic infectious disease serious harm to human health, is mainly composed of Mycobacterium tuberculosis infection. When Mycobacterium tuberculosis entered into the human body and led immune macrophage reaction, some strains were long-term survival and made reproduction, which is the decisive factor leading to tuberculosis. In the early stage of infection, Mycobacterium tuberculosis growth was inhibited by apoptosis of macrophages. With the increase of high titer, high virulent strains breeding rate, the effect of macrophage on apoptosis increases ceaselessly, and make their own reproduction can be effectively protected, providing sufficient, appropriate intracellular environment for the growth of strains. Therefore, the inhibition of Mycobacterium tuberculosis to the regulation of macrophage apoptosis process is the key to the prevention and treatment of tuberculosis.

Key words: Macrophage; apoptosis; Mycobacterium tuberculosis; infection; mechanism; progress

Chinese Library Classification(CLC): R378.911, R52 **Document code:** A

Article ID: 1673-6273(2014)05-972-03

前言

结核分枝杆菌(Mycobacterium tuberculosis, MTB)是引起结核病的主要病原菌, 可造成全身各器官感染, 其中以肺结核最为常见^[1]。巨噬细胞是一种免疫细胞, 可参与机体非特异性免疫和特异性免疫, 是人体免疫防御系统第一道防线的重要组成部分, 在抗结核分枝杆菌感染中可起到重要作用。研究表明, MTB 可对巨噬细胞的凋亡产生诱导作用, 从而逃避免疫监视和免疫防御, 使疾病进展速度增加^[2]。目前, 全球每年新发结核病患者高达 1000 万, 死亡约 300 万, 结核病感染现状不容乐观^[3]。因此, 探讨巨噬细胞凋亡对结核分枝杆菌感染的机制, 对进一

步明确结核病发病机理、制定治疗措施具有重要意义。

1 结核分枝杆菌的致病机制

1.1 胞内寄生

MTB 形态细长, 略带弯曲, 其细胞壁脂质肽聚糖外层包裹有大量分枝菌酸, 属非运动性细菌^[4]。与大多数胞外病原菌感染机制相比, MTB 不会分泌毒素来创造合适的生存环境, 而是通过感染巨噬细胞, 使其自身被巨噬细胞吞噬后, 阻止 ATP/ 质子泵的进入, 同时, 吞噬小泡的酸化作用使非致病菌被降解, 胞内 pH 降低, 为 MTP 的繁殖创造了合适的环境^[5]。Sakala IG 等^[6]研究发现, 巨噬细胞缺陷型小鼠在经 MTB 感染时结核病发病率

* 基金项目: 国家自然科学基金项目(J1103520)

作者简介: 于翔 (1990-), 男, 本科, 研究方向: 植物抗逆, 电话: 15610795300

△ 通讯作者: 杨永青, 男, 副教授, 研究方向: 植物抗旱

(收稿日期: 2013-07-11 接受日期: 2013-08-10)

较低,提示肺泡巨噬细胞内质体与 MTB 融合后,可对 MTB 的生长、繁殖起到一定的保护作用,促进了 MTB 感染。

1.2 细胞凋亡

细胞凋亡是一种程序性细胞死亡,是一个主动过程,主要目的为维持内环境的稳定。巨噬细胞可识别出现标记信号的凋亡细胞,产生和释放转化生长因子- β (TNF- β)、白介素-10 (IL-10)等抗炎介质,起到防御胞内寄生菌的作用^[7]。感染早期的巨噬细胞凋亡是机体自我防御的表现,可有效清除部分寄生的 MTB,降低 MTB 体内播散速度,而随着巨噬细胞凋亡数量的增加,MTB 分泌的自身毒力因子、蛋白质及毒素成分可起到强抗凋亡作用,加快了病情进展速度^[8]。

2 巨噬细胞凋亡对结核分枝杆菌感染的机制

2.1 正向调控机制

2.1.1 酶活性的影响 机体受 MTB 感染后,巨噬细胞会产生大量 TNF- α 和 IL-1 β ,使蛋白激酶 Caspase 酶系活性上升,其中以 Caspase-1 活性上升最为显著^[9]。研究证实,Caspase-1 是启动巨噬细胞凋亡过程中最重要的酶,使用 ICE 抑制剂 YVAD 抑制 Caspase-1 后,患者巨噬细胞凋亡速度明显降低,说明 MTB 感染引发的蛋白激酶活性提高是加剧细胞凋亡的基础因素。

2.1.2 前炎症因子的影响 IL-1、IL-6、IL-8、TNF- α 等前炎症因子可导致炎症反应的出现,对 MTB 感染引发的免疫反应起到了重要影响。Divangahi M 等^[10]指出,TNF- α 可激活巨噬细胞与凋亡有关的基因表达,是细胞凋亡的主要环节,其机制主要为:在第二信号胞质磷脂酶 A2 (Cytosolic phospholipase A2, cPLA2) 的刺激下,巨噬细胞表面的 TNFR1 可与 TNF- α 结合,而结合后的物质可被半胱氨酸蛋白水解酶所裂解,从而激活 Caspase-2 及 Caspase-3,启动凋亡过程。同时,Patil AG 等^[11]认为,MTB 诱导巨噬细胞产生的 IL-10,使 TNF- α 活性受到抑制,降低了被 MTB 感染的宿主细胞巨噬细胞凋亡的速度。上述两种机制互相作用,使未被感染的巨噬细胞数量减少,而受到 MTB 感染的巨噬细胞凋亡速度降低,加剧了病程的进展^[12]。

2.1.3 转导途径的激活 MTB 对 JAK2/STAT1- α 信号转导途径的激活已得到广泛共识^[13],其主要是通过酪氨酸蛋白激酶 (Protein Tyrosine Kinase, PTK) 的激活,使 JAK2/STAT1- α 磷酸化,而作为蛋白酪氨酸磷酸激酶的 JAK2 和作为信号传递与转录激活因子的 STAT1- α 受到活化后,会引发细胞产生大量 TNF- α 及 NO^[14],使蛋白激酶 Caspase 酶系活性上升,促进了凋亡的进展。而姚楠等^[15,29-30]研究发现,MTB 中蛋白质成分葡萄糖脂蛋白 19000 (P19) 可使 Caspase-8 激活,诱导细胞凋亡的发生。

2.1.4 凋亡蛋白的表达 Bcl-2 蛋白家族可改变细胞凋亡阈值,从而启动凋亡信号。Morris D 等^[16]指出,机体受到 MTB 感染后,Bcl-2 和 Bax 会呈现高表达,使抗凋亡信号和促凋亡信号比例失衡,诱导正常细胞凋亡,同时保证 MTB 在宿主细胞中的存活。

2.1.5 线粒体的损伤 细胞受 MTB 感染后,会出现线粒体外膜改变、膜电位消失、通透性转运孔开放等变化,使线粒体破裂数量上升,而 Kleynhans L 等^[17,31-32]证实,线粒体在细胞凋亡中可起到重要枢纽作用。因此,当破裂的线粒体数量显著上升时,胞质中可溶性蛋白亦随之上升,启动了核凋亡的发生^[18,33-35]。

2.2 反向调控机制

2.2.1 MTB 成分对凋亡的调控 MTB 含结核菌酸、索状因子等菌体成分,具有一定的抑制细胞凋亡作用^[19],其细胞壁中的甘露糖末端脂阿拉伯甘露聚糖 (ManLAM) 可抑制巨噬细胞蛋白激酶 C (PKC) 活性,使 PKC 去活化,从而降低 IFN- γ 及 HLA-DR-A 基因表达,抑制 ATP/Ndk 诱导的细胞凋亡过程^[20],有助于保护 MTB 在宿主细胞中的生长、繁殖。

2.2.2 毒力对凋亡的影响 MTB 对 IL-10 的生成具有促进作用,而不同毒力的 MTB 株会在巨噬细胞凋亡机制下表现出不同的结局^[21],如 H37Rv 毒力最强,其刺激生成 IL-10 数量最多,从而诱导更多的 sTNFR2 生成,使 TNF 生物学活性受到抑制,细胞凋亡速度降低、数量减少,使该毒株在宿主细胞内生长、繁殖速度最快^[22]。因此,Luo X 等^[23]认为,不同毒力的 MTB 株对巨噬细胞凋亡机制的逃避能力不同,毒力较强的毒株,在胞内代谢率越高,则细胞凋亡速度越低。

3 结语

近年来,随着社会经济的发展和人口流动速度的增加,感染性疾病已成为导致人类死亡的重要疾病^[24]。20 世纪 80 年代以来,MTB 耐药菌株的增加使全球结核病疫情再度爆发,目前,全球每年新发结核病 1000 万人次,死亡 300 万人,而我国现有 MTB 感染者 4 亿人,每年因结核病死亡的人数超过 25 万^[25]。不论是世界范围内还是就我国而言,结核病疫情已十分严峻,也为结核病的防治工作提出了较高要求。MTB 感染首要步骤为侵袭巨噬细胞,并在巨噬细胞内寄生,但巨噬细胞的凋亡可使 MTB 生存环境受到抑制,使其在体内的传播速度降低^[26],而 MTB 又可抑制巨噬细胞的凋亡,使受感染细胞得到保护。因此,探究巨噬细胞凋亡对 MTB 感染的机制,是指导临床治疗、预防和控制结核病疫情蔓延的重中之重。

在综合文献资料及研究成果后,我们发现,MTB 可通过多种机制达到对巨噬细胞凋亡的调控效果,首先,MTB 的入侵会使宿主巨噬细胞内在活性激活,使 TNF- α 介导的凋亡机制启动,使巨噬细胞早期抵御 MTB 效果良好,菌株生长受到抑制;而随着凋亡的进展,MTB 利用细胞凋亡引发的坏死达到了脱离巨噬细胞的作用^[27,28],使未感染的巨噬细胞受到感染;最终,高效价、强毒力的 MTB 使巨噬细胞凋亡受到抑制,为其进一步生长繁殖提供了充足空间,导致重症结核病的发生。

综上所述,在免疫防御的早期,MTB 的生长繁殖可因感染细胞的凋亡而受到抑制,而细胞凋亡导致吞噬体数目的降低使宿主细胞免疫反应受到干扰,MTB 抗凋亡逐渐占主导趋势,是引发炎症反应和病情进展的主要原因。因此,在结核病的治疗及防控中,应注重对 MTB 在胞内代谢的控制,从而抑制其抗凋亡进程,促进菌株扩散,防止感染进展。

参考文献 (References)

- [1] Guirado E, Schlesinger LS. Modeling the Mycobacterium tuberculosis Granuloma-the Critical Battlefield in Host Immunity and Disease [J]. Front Immunol, 2013, 22(4):98-98
- [2] Nalpas NC, Park SD, Magee DA, et al. Whole-transcriptome, high-throughput RNA sequence analysis of the bovine macrophage response to Mycobacterium bovis infection in vitro [J]. BMC Genomics, 2013, 14 (1):230-230

- [3] Heuts F, Gavier-Widén D, Carow B, et al. CD4⁺ cell-dependent granuloma formation in humanized mice infected with mycobacteria[J]. *Proc Natl Acad Sci U S A*, 2013, 110(16):6482-6487
- [4] 张薇, 柏银兰, 康健, 等. 结核分枝杆菌持续感染期抗原 Rv1733c 的表达、纯化和鉴定[J]. *现代生物医学进展*, 2012, 12(10): 1868-1871
Zhang Wei, Bai Yin-lan, Kang Jian, et al. The expression of antigen Rv1733c, persistent infection with *Mycobacterium tuberculosis* purification and identification of [J]. *Progress in modern biomedicine*, 2012, 12(10): 1868-1871
- [5] Singh AK, Abhimanyu, Yadav AB, et al. HLA-DRB1*1501 and VDR polymorphisms and survival of *Mycobacterium tuberculosis* in human macrophages exposed to inhalable microparticles[J]. *Pharmacogenomics*, 2013, 14(5):531-540
- [6] Sakala IG, Eickhoff CS, Blazevic A, et al. Dipterinyl Calcium Pentahydrate Inhibits Intracellular Mycobacterial Growth in Human Monocytes via the C-C Chemokine MIP-1 β and Nitric Oxide[J]. *Infect Immun*, 2013, 81(6):1974-1983
- [7] Jayaraman P, Sada-Ovalle I, Nishimura T, et al. IL-1 β promotes antimicrobial immunity in macrophages by regulating TNFR signaling and caspase-3 activation[J]. *J Immunol*, 2013, 190(8):4196-4204
- [8] Kumar S, Dwivedi AP, Kashyap VK, et al. Synthesis and biological evaluation of trans 6-methoxy-1, 1- dimethyl-2-phenyl-3-aryl-2, 3-dihydro-1H-inden-4-yloxyalkylamine derivatives against drug susceptible, non-replicating *M. tuberculosis* H37Rv and clinical multidrug resistant strains[J]. *Bioorg Med Chem Lett*, 2013, 23(8):2404-2407
- [9] 郭旭光, 夏勇, 马越云, 等. 肺上皮细胞自噬体在结核分枝杆菌感染中保护作用的分子机制 [J]. *现代生物医学进展*, 2011, 11(21): 4019-4023
Guo Xu-guang, Xia Yong, Ma Yue-yun, et al. Lung epithelial cell autophagy in *Mycobacterium tuberculosis* infection protection molecular machine [J]. *progress in modern biomedicine*, 2011, 11(21): 4019-4023
- [10] Divangahi M, Behar SM, Remold H. Dying to live: how the death modality of the infected macrophage affects immunity to tuberculosis [J]. *Adv Exp Med Biol*, 2013, 783:103-120
- [11] Patil AG, Sang PB, Govindan A, et al. Mycobacterium tuberculosis MutT1 (Rv2985) and ADPRase (Rv1700) Proteins Constitute a Two-stage Mechanism of 8-Oxo-dGTP and 8-Oxo-GTP Detoxification and Adenosine to Cytidine Mutation Avoidance [J]. *J Biol Chem*, 2013, 288(16):11252-11262
- [12] 王建军, 陈猷, 谢萍芳, 等. 鸟结核分枝杆菌感染巨噬细胞后的外泌体刺激巨噬细胞产生的细胞因子及其蛋白质表达改变[J]. *细胞与分子免疫学杂志*, 2013, 29(2): 123-126, 131
Wang Jian-jun, Chen Cai, Xie Ping-fang, et al. Cytokines and protein changes in stimulate macrophages to produce bird infection with *Mycobacterium tuberculosis* exosome macrophages [J]. *Journal of cellular and molecular immunology*, 2013, 29(2): 123-126, 131
- [13] Sato E, Imafuku S, Ishii K, et al. Vitamin D-dependent cathelicidin inhibits *Mycobacterium marinum* infection in human monocytic cells [J]. *J Dermatol Sci*, 2013, 70(3):166-172
- [14] Subbian S, O'Brien P, Kushner NL, et al. Molecular immunologic correlates of spontaneous latency in a rabbit model of pulmonary tuberculosis[J]. *Cell Commun Signal*, 2013, 11(1):16-16
- [15] 姚楠, 董江涛, 徐芳, 等. 结核分枝杆菌 Hsp16.3 与感染巨噬细胞凋亡的相关性研究[J]. *中国病原生物学杂志*, 2012, 7(8): 569-573
Yao Nan, Dong Jiang-tao, Xu Fang, et al. Study on the correlation between *Mycobacterium tuberculosis* Hsp16.3 and infected macrophage apoptosis [J]. *Journal of Pathogen Biology*, 2012, 7(8): 569-573, e2
- [16] Morris D, Guerra C, Khurasany M, et al. Glutathione Supplementation Improves Macrophage Functions in HIV[J]. *J Interferon Cytokine Res*, 2013, 33(5):270-279
- [17] Kleynhans L, Du Plessis N, Allie N, et al. The contraceptive depot medroxyprogesterone acetate impairs mycobacterial control and inhibits cytokine secretion in mice infected with *Mycobacterium tuberculosis*[J]. *Infect Immun*, 2013, 81(4):1234-1244
- [18] 虞清章, 张万江. 结核分枝杆菌感染中巨噬细胞凋亡的研究进展 [J]. *中国人兽共患病学报* 2012; 28(5): 496-499
Tuo Qing-zhang, Zhang Wan-jiang. Apoptosis in macrophages infected with *Mycobacterium tuberculosis* research [J]. *Chinese Journal of zoonoses*, 2012, 28(5): 496-499
- [19] Francisco-Cruz A, Mata-Espinosa D, Estrada-Parra S, et al. Immunotherapeutic effects of recombinant adenovirus encoding granulocyte-macrophage colony-stimulating factor in experimental pulmonary tuberculosis[J]. *Clin Exp Immunol*, 2013, 171(3):283-297
- [20] Salamon H, Qiao Y, Cheng JC, et al. Evidence for postinitiation regulation of mRNA biogenesis in tuberculosis [J]. *J Immunol*, 2013, 190(6):2747-2755
- [21] Martinez AN, Mehra S, Kaushal D. Role of interleukin 6 in innate immunity to *Mycobacterium tuberculosis* infection [J]. *J Infect Dis*, 2013, 207(8):1253-1261
- [22] 董江涛, 徐芳, 田玺择, 等. 不同毒力结核分枝杆菌感染小鼠对肺泡巨噬细胞的凋亡率及其时相性变化的影响 [J]. *中国免疫学杂志*, 2012, 28(5): 389-392
Dong Jiang-tao, Xu Fang, Tian Xi-ze, et al. different virulence of *Mycobacterium tuberculosis* infection rate of apoptosis of alveolar macrophages of mice and its phasic change [J]. *Chinese Journal of immunology*, 2012, 28(5): 389-392
- [23] Luo X, Pires D, Afonso JA, et al. Zanthoxylum capense constituents with antimycobacterial activity against *Mycobacterium tuberculosis* in vitro and ex vivo within human macrophages [J]. *J Ethnopharmacol*, 2013, 146(1):417-422
- [24] Russell DG. The evolutionary pressures that have molded *Mycobacterium tuberculosis* into an infectious adjuvant[J]. *Curr Opin Microbiol*, 2013, 16(1):78-84
- [25] Klug-Micu GM, Stenger S, Sommer A, et al. CD40 ligand and interferon- γ induce an antimicrobial response against *Mycobacterium tuberculosis* in human monocytes[J]. *Immunology*, 2013, 139(1):121-128
- [26] Kovjazin R, Shitrit D, Preiss R, et al. Characterization of novel multi-antigenic vaccine candidates with pan-HLA coverage against *Mycobacterium tuberculosis*[J]. *Clin Vaccine Immunol*, 2013, 20(3):328-340
- [27] Slight SR, Rangel-Moreno J, Gopal R, et al. CXCR5⁺ T helper cells mediate protective immunity against tuberculosis [J]. *J Clin Invest*, 2013, 123(2):712-726

- targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction.[J].Blood,2006,107(11): 4532-4539
- [9] Puttini M, Coluccia AM, Bosehelli F, et al. In vitro and in vivo activity of SKI-606, a novel Src-Ahl inhibitor, against imatinib-resistant Bcr-Abl+ neoplastic cells[J]. Cancer Res, 2006, 66(23): 11314-11322
- [10] Konig H, Holyoake TL, Bhatia R. Effective and selective inhibition of chronic myeloid leukemia primitive hematopoietic progenitors by the dual Src/Abl kinase inhibitor SKI-606 [J]. Blood, 2008, 11(4): 2329-2338
- [12] Parker WT, Ho M, Scott HS, et al. Poor response to second-line kinase inhibitors in chronic myeloid leukemia patients with multiple low-level mutations, irrespective of their resistance profile [J].Blood, 2012, 119(10): 2234-2238
- [13] O'Hare T, Shakespeare WC, Zhu X, et al. AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance [J].Cancer Cell, 2009, 16(5):401-412
- [14] Champlin R, Jabbour E, Kebriaei P, et al. Allogeneic stem cell transplantation for chronic myeloid leukemia resistant to tyrosine kinase inhibitors [J]. Clin Lymphoma Myeloma Leuk, 2011, Suppl 1:S96-100
- [15] Jabbour E, Cortes J, Kantarjian H, et al. Novel tyrosine kinase inhibitor therapy before allogeneic stem cell transplantation in patients with chronic myeloid leukemia: no evidence for increased transplant-related toxicity[J].Cancer, 2007,110(2):340-344
- [16] Carpenter PA, Snyder DS, Flowers ME, et al. Prophylactic administration of imatinib after hematopoietic celltransplantation for high-risk Philadelphia chromosome-positiveleukemia [J]. Blood,2007, 109(7): 2791-2793
- [17] Radich JP, Gooley T, Bryant E, et al. The significance of bcr-abl molecular detection in chronic myeloid leukemia patients "late," 18 months or more after transplantation [J]. Blood, 2001, 98(6):1701-1707
- [18] Palandri F, Castagnetti F, Iacobucci I, et al. The response to imatinib and interferon-alpha is more rapid than the response to imatinib alone: a retrospective analysis of 495 Philadelphia-positive chronic myeloid leukemia patients in early chronic phase [J]. Haematologica, 2010, 95: 1415,141
- [19] Azam M. An in vitro screening to identify drug-resistant mutations for target-directed chemotherapeutic agents [J]. Methods Mol Biol, 2012, 928:175-84
- [20] Deininger M, Buchdunger E, Druker BJ. The development of imatinib as a therapeutic agent for chronic myeloid leukemia [J] . Blood, 2005, 105 (7):2640-2653

(上接第 974 页)

- [28] 刘来成, 王淑玲, 卢贤瑜, 等. 结核杆菌 H37Ra 感染巨噬细胞的研究[J]. 细胞与分子免疫学杂志, 2011, 27(11): 1195-1197
- Liu Lai-cheng, Wang Shu-ling, Lu Xian-yu, et al. H37Ra of Mycobacterium tuberculosis infection of macrophage cell and molecular study of [J]. Chinese Journal of Cellular and Molecular Immunology, 2011, 27 (11): 1195-1197
- [29] Lee HM, Kang J, Lee SJ, et al. Microglial activation of the NLRP3 inflammasome by the priming signals derived from macrophages infected with mycobacteria[J]. Glia, 2013, 61(3):441-452
- [30] Lim YJ, Choi HH, Choi JA, et al. Mycobacterium kansasii-induced death of murine macrophages involves endoplasmic reticulum stress responses mediated by reactive oxygen species generation or calpain activation[J]. Apoptosis, 2013, 18(2):150-159
- [31] Podinovskaia M, Lee W, Caldwell S, et al. Infection of macrophages with Mycobacterium tuberculosis induces global modifications to phagosomal function[J]. Cell Microbiol, 2013, 15(6):843-859
- [32] Walters SB, Kieckbusch J, Nagalingam G, et al. Microparticles from mycobacteria-infected macrophages promote inflammation and cellular migration[J]. J Immunol, 2013, 190(2):669-677
- [33] Singh Y, Kaul V, Mehra A, et al. Mycobacterium tuberculosis controls microRNA-99b (miR-99b) expression in infected murine dendritic cells to modulate host immunity [J]. J Biol Chem, 2013, 288(7): 5056-5061
- [34] 李娜, 刘鹏飞, 李波清, 等. Ipr1 对巨噬细胞抗结核分枝杆菌感染免疫相关基因表达的影响 [J]. 中国人兽共患病学报, 2011, 27 (8): 715-720
- Li Na, Liu Peng-fei, Li Bo-qing, et al. Effect of Ipr1 against tuberculosis immune related gene expression in macrophages infected with Mycobacterium tuberculosis [J]. Chinese Journal of zoonoses, 2011, 27 (8): 715-720
- [35] Verma RK, Germishuizen WA, Motheo MP, et al. Inhaled microparticles containing clofazimine are efficacious in treatment of experimental tuberculosis in mice[J]. Antimicrob Agents Chemother, 2013, 57 (2):1050-1052